Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment.
Shaji Kumar
Consultant or Advisory Role - Celgene; Merck
Honoraria - Merck
Research Funding - Celgene; Genzyme; Millennium; Novartis
William Bensinger
Consultant or Advisory Role - Celgene; Millennium
Honoraria - Celgene
Research Funding - Celgene; Millennium; Onyx
Todd M. Zimmerman
Honoraria - Celgene (I); Millennium
Craig B. Reeder
Research Funding - Celgene; Millennium; Novartis
James R. Berenson
Consultant or Advisory Role - Amgen; Celgene; Millennium; Novartis; Onyx
Honoraria - Amgen; Celgene; Millennium; Onyx
Research Funding - Amgen; Celgene; Millennium; Novartis; Onyx
Deborah Berg
Employment or Leadership Position - Millennium
Ai-Min Hui
Employment or Leadership Position - Millennium
Neeraj Gupta
Employment or Leadership Position - Millennium
Alessandra Di Bacco
Employment or Leadership Position - Millennium
Jiang Yu
Employment or Leadership Position - Millennium
Yaping Shou
Employment or Leadership Position - Millennium
Ruben Niesvizky
Consultant or Advisory Role - Celgene; Millennium; Onyx
Research Funding - Celgene; Millennium; Onyx